title: A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
abstract: BACKGROUND
  The sensitivity of mammography for the detection of small lesions, including node-negative early-stage (T1N0) primary breast cancer (PBC) and ductal carcinoma in situ (DCIS), is significantly decreased in young patients. From a clinical standpoint, an inconclusive mammogram reflects the inability of clinicians to confidently decide whether patients should be referred for biopsy or for follow-up with repeat imaging.
  
  
  METHODS
  Specific ELISAs were developed for a panel of 13 well-recognized breast autoantigens (HSP60, FKBP52, PRDX2, PPIA, MUC1, GAL3, PAK2, P53, CCNB1, PHB2, RACK1, RUVBL1, and HER2). Circulating autoantibody levels were measured in a cohort of 396 serum samples from histologically confirmed DCIS (n = 87) or T1N0 PBC (n = 153) and healthy controls (n = 156).
  
  
  RESULTS
  Individually, antibodies against CCNB1, FKBP52, GAL3, PAK2, PRDX2, PPIA, P53, and MUC1 demonstrated discriminatory power between breast cancer and healthy control groups. At 90% sensitivity, the overall combined specificity of the autoantibody serum screening test was 42%. Adjustment for higher sensitivities of 95% and 99% resulted in 30% and 21% specificities, respectively (33% and 18% in T1N0 PBC and 28% and 21% in DCIS). Finally, in patients with node-negative early-stage breast cancer younger than 50 years, the autoantibody assay exhibited 59% specificity with a fixed sensitivity at 90%.
  
  
  CONCLUSIONS
  Our autoantibody panel allows accurate detection of early breast cancer and DCIS, notably in younger patients.
  
  
  CONCLUSIONS
  Clinical assessment of this autoantibody panel displays a potential to facilitate clinical management of early-stage breast cancer detection in cases of inconclusive mammogram.
authors: CHU Montpellier, Arnaud de Villeneuve, Department of Biopathology, Montpellier, France. University of Montpellier I, Montpellier, France. CRLC Val d'Aurelle, Department of Clinical Oncoproteomics, Montpellier, France.
authors: Jérôme
authors: J
authors: Lacombe
authors: CHU Montpellier, Arnaud de Villeneuve, Department of Biopathology, Montpellier, France. University of Montpellier I, Montpellier, France. CRLC Val d'Aurelle, Department of Clinical Oncoproteomics, Montpellier, France.
authors: Alain
authors: A
authors: Mangé
authors: CHU Montpellier, Arnaud de Villeneuve, Department of Biopathology, Montpellier, France. University of Montpellier I, Montpellier, France. CRLC Val d'Aurelle, Department of Clinical Oncoproteomics, Montpellier, France.
authors: Anne-Claire
authors: AC
authors: Bougnoux
authors: Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Lunenfeld Tanenbaum Research Institute, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
authors: Ioannis
authors: I
authors: Prassas
authors: CHU Montpellier, Arnaud de Villeneuve, Department of Biopathology, Montpellier, France. University of Montpellier I, Montpellier, France. CRLC Val d'Aurelle, Department of Clinical Oncoproteomics, Montpellier, France. j-solassol@chu-montpellier.fr.
authors: Jérôme
authors: J
authors: Solassol
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood* / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008327:Mammography; D008875:Middle Aged; D000091402:Prohibitins
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; C000717331:PHB2 protein, human; D000091402:Prohibitins